John Varga, MD, FACP, MACR
Manage Your Profile
About
John Varga MD attended Columbia University in New York, and obtained his medical degree from New York University. He completed Internal Medicine Residency at Rhode Island Hospital in Providence and Rheumatology Fellowship at Boston University. Following post-doctoral research at the University of Pennsylvania, he was on the faculty of the University of Illinois and Northwestern University in Chicago, and recently was recruited to Chief of Rheumatology at the University of Michigan. For the past three decades, Varga’s research has focused on fibrosis and the application of precision medicine approaches to improve patient outcomes. His lab, continuously funded by the NIH, investigates immunological and cellular mechanisms of fibrosis. He has served as a charter member of the NIH ACTS Study section and Co-Editor of Arthritis and Rheumatology, and is a member of the ACR Board of Directors. He is the author of more than 380 journal articles and book chapters and three textbooks. He has mentored over 20 post-doctoral MD and PhD trainees, many of whom have gone on to develop successful academic or industry careers.
Links
John Varga Sclerolab
Qualifications
-
Post-doctoral Research Fellow, T32University of Pennsylvania, Philadelphia, United States
1985 - 1987
-
Rheumatology FellowBoston University School of Medicine, Boston, United States
1983 - 1985
-
Intern and Resident in MedicineRhode Island Hospital/Brown, United States
1980 - 1983
-
MDNew York University School of Medicine, New York, NY, United States
1978 - 1980
-
BAColumbia University, New York, United States
1971 - 1975
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberGlobal REACH
-
Center MemberCenter for Computational Medicine and Bioinformatics
Research Overview
My lab studies inflammation and metabolism in the context of chronic autoimmune and fibrotic diseases. We use mouse models, patient samples, genetics and genomics to identify mechanisms of disease and novel targets for therapy. Our research is patient-oriented and we embrace of a tight "bench-to-bedside-to bench" approach. Our Michigan Scleroderma Program afford unique access to patients including genetics and biological specimen, for our research, including early-stage clinical trials.
Visit the John Varga Sclerolab website: https://medresearch.umich.edu/labs-departments/labs/sclerolab
Recent Publications
-
Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA, Barker JN, Weidinger S, Modlin RL, Betz RC, Khanna D, Varga J, Kahlenberg JM, He K, Elder JT, Zhou X, Gudjonsson JE, Tsoi LC. J Allergy Clin Immunol, 2026 May 26;Journal ArticleMulti-cytokine based TWAS for seven inflammatory skin disorders identify candidate causal genes in keratinocytes.
DOI:10.1016/j.jaci.2026.05.013 PMID: 42203178 -
Wells R, Caballero-Ruiz B, Mulipa P, Timmis AJ, Teves ME, Varga J, Del Galdo F, Ross RL, Riobo-Del Galdo NA. Arthritis Res Ther, 2026 May 7;Journal ArticleAurora A kinase activation contributes to the fibrotic phenotype in systemic sclerosis through primary cilia shortening.
DOI:10.1186/s13075-026-03826-6 PMID: 42098768 -
Wells R, Ruiz BC, Mulipa P, Timmis AJ, Teves ME, Varga J, Del Galdo F, Ross RL, Galdo NAR-D. 2026 Mar 18; bioRxiv,PreprintAurora A kinase activation contributes to the fibrotic phenotype in Systemic Sclerosis through primary cilia shortening
DOI:10.64898/2026.03.13.711548 -
Shah K, Verma P, Hamil T, Dey P, Bale S, Yalavarthi B, Tsou P-S, Gudjonsson JE, Khanna D, Varga J, Bhattacharyya S. J Invest Dermatol, 2026 Mar 6;Journal ArticleNintedanib Attenuates Profibrotic Gene Expression in a 3D Organotypic Culture Model of Systemic Sclerosis Skin Fibrosis.
DOI:10.1016/j.jid.2026.01.046 PMID: 41796853 -
Su EJ, Tsou P-S, Warnock M, Subbotina N, Mann K, Vichaikul S, Rosek A, Leung L, Xing X, Xing E, Plazyo O, Bogle R, Tsoi LC, Emal CD, Khanna D, Varga J, Sisson TH, Gudjonsson JE, Lawrence DA. JCI Insight, 2026 Feb 17;Journal ArticleA potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model.
DOI:10.1172/jci.insight.195005 PMID: 41701900 -
Verma P, Goncalves RM, Bale S, Silverman J, Hamill T, Shah K, Yalavarthi B, Bhattacharyya D, Bhattacharyya S, Varga J. 2026 Feb 5; bioRxiv,PreprintTargeting activated IL-23 signaling in Scleroderma by tildrakizumab
DOI:10.64898/2026.01.30.701821 -
Guo W, Li Z, Xu D, Li T, Li X, Fang D, Zhang X, Jin Y, Xing D, Chen Z, Yuan X, Wang Z, Dong C, Xu H, Varga J, Wang J, Ge J, Mu R. British Journal of Dermatology, 2026 Feb 1; 194 (2): 326 - 339.Journal ArticleCCL19+fibroblast-CCR7+T-cell crosstalk coordinates immunofibrotic signalling networks in systemic sclerosis
DOI:10.1093/bjd/ljaf444 PMID: 41321019 -
Dal Santo T, Carrier ME, Nassar EL, Dal Santo C, Hu S, Kwakkenbos L, Bartlett SJ, Fox RS, Lee YC, Varga J, Thombs BD, McKenzie JAL, Lawrie-Jones A, Mieszczak T, Sauve M. Rheumatology, 2026 Feb 1; 65 (2):Journal ArticleDevelopment of a tool to map SSc pain sources, characteristics and management experiences: The SPIN Pain Assessment Tool
DOI:10.1093/rheumatology/keag039 PMID: 41578942
Featured News & Stories
Compassionate gifts turn heartbreak into hope
Dr. John Varga Honored with Prestigious Lifetime Achievement Award